Skip to main content

Table 3 Subjective patient-reported improvements over the study period

From: Neurological, functional, and quality of life outcomes following combined mesenchymal stem cell and Schwann cell therapy in spinal cord injury: a 9-year experience

 

Baseline

6-month

12-month

P-valuea

Trunk Movement

No

37 (35.3%)

23 (22.4%)

23 (22.4%)

0.003*

Yes

68 (64.7%)

82 (77.6%)

82 (77.6%)

 

Ability to Sit

No

31 (29.4%)

13 (12.9%)

13 (12.9%)

< 0.001*

Yes

74 (70.6%)

92 (87.1%)

92 (87.1%)

 

Equilibrium in Sitting Position

No

87 (82.4%)

31 (29.4%)

31 (29.4%)

< 0.001*

Yes

18 (17.6%)

74 (70.6%)

74 (70.6%)

 

Equilibrium in Standing Position

No

91 (86.7%)

51 (48.2%)

51 (48.2%)

< 0.001*

Yes

14 (13.3%)

54 (51.8%)

54 (51.8%)

 

Bladder Filling Sensation

No

79 (75.0%)

58 (55.6%)

58 (55.6%)

0.016*

Yes

26 (25.0%)

47 (44.4%)

47 (44.4%)

 

Voluntary Bladder Control

No

97 (91.7%)

76 (72.2%)

76 (72.2%)

0.016*

Yes

8 (8.3%)

29 (27.8%)

29 (27.8%)

 

Any Anal Sensation

No

85 (80.6%)

73 (69.4%)

73 (69.4%)

0.125

Yes

20 (19.4%)

32 (30.6%)

32 (30.6%)

 

Voluntary Anal Contraction

No

94 (88.9%)

91 (86.1%)

91 (86.1%)

1.00

Yes

11 (11.1%)

14 (13.9%)

14 (13.9%)

 
  1. a McNemar’s test was performed to compare categorical outcomes at the 12-month follow-up with baseline
  2. * Indicates statistically significant